A sthma is the most common chronic disease of childhood, and although population-based rates of asthma-related hospital admission are decreasing (1) , receipt of intensive care is increasing (2) . National and international expert panels (3, 4) have enumerated stepwise care for chronic asthma with an emphasis on controller medication use and symptom based care plans (5, 6) , but guidelines for critical childhood asthma care, defined as requiring admission to a pediatric intensive care unit (PICU), are not formally established.
Several factors limit advances to refine PICU asthma care. Currently, there is wide practice variation for care of the severely ill child with asthma (7) (8) . Furthermore, studies of pediatric critical asthma care are hampered by lack of a consistent and reproducible outcome measures. Most children cannot reliably perform pulmonary function testing during an exacerbation and mortality from severe asthma is rare. Reported outcomes include length of PICU stay, need for mechanical respiratory support (7, 9, 10) , or toxicity from therapy (11) (12) (13) . However, length of stay (LOS) is often affected by factors extraneous to the patient such as census, nurse staffing, and time of day, whereas need for intubation may be subjective.
Wide variation in care presents opportunities for improvement and research equipoise for future studies (14) . The objective of this study was to describe current pediatric severe asthma care, complications, and outcomes to inform plans for future studies by the Collaborative Pediatric Critical Care Research Network (CPCCRN) (15) . We evaluated PICU medical therapies and mechanical support for asthma care at the CPCCRN centers that submit data to the Pediatric Health Information System (PHIS) to determine whether therapies differed among CPCCRN centers. We also compared care between CPCCRN and non-CPCCRN centers to assess if the CPCCRN centers are representative of pediatric asthma care in U.S. free-standing children's hospitals that contribute to PHIS. Receipt of mechanical respiratory support, LOS, complications, and readmission were evaluated as potential outcomes for future severe asthma studies.
MATERIALS AND METHODS
Data Source. The CPCCRN (15) is a multicentered research network. We developed a critical asthma research design and development project to evaluate current practices and variability in asthma care through examination of PHIS, collected by Children's Health Corporation of America (CHCA) (16) . CHCA is a collaboration of >40 children's hospitals, and PHIS contains administrative data including demographics, diagnoses, procedures, and charges. Six of eight CPCCRN sites contribute to PHIS (16) . All PHIS data are de-identified and checked for reliability and validity before release. Clinical Transaction Classification is a proprietary system used by PHIS to categorize hospital billing for clinical, imaging, laboratory, pharmacy, supply, and other services. The centers for Medicare and Medicaid are adopting Clinical Transaction Classification for medication billing (17) . However, the actual provision of a medication or service to a patient cannot be verified. (18) Readmission (emergency department, hospital ward, and PICU) for asthma after the initial PICU admission was tracked during the study period.
The University of Utah Institutional Review
Outcomes. Receipt and duration of noninvasive and invasive ventilation, LOS in the PICU and hospital, duration of ventilation, complications, and mortality were evaluated. Tracheal intubation in the PICU was defined as either a procedure code for intubation or a procedure code for both noninvasive ventilation and invasive ventilation during the first PICU day. The PHIS database tracks procedures and charges by calendar day, and the assumption was made that noninvasive ventilation typically preceded invasive ventilation.
Analysis. Hospitals were designated as either CPCCRN or non-CPCCRN centers. Variation in asthma therapies between CPCCRN and non-CPCCRN centers was evaluated to determine whether the CPCCRN sites are representative of severe PICU asthma care in U.S. children's hospitals. Therapies, monitoring, and outcomes among CPCCRN centers were compared to evaluate patterns of care and to evaluate potential outcomes for clinical trials. Receipt of asthma therapies based on charges for medications and mechanical support were evaluated for all cases and the subset treated with either noninvasive or invasive ventilation. Data were described using median values with 25 th and 75 th quartiles or as percentages and were compared using the Kruskal-Wallis H test or the chi-square test. A Bonferroni adjustment for statistical significance was used when making multiple pair-wise comparisons of continuous data with the analysis regarding site of intubation; however, variation within CPCCRN centers was not tested for multiple comparisons, because variation across centers was the question of interest, not whether specific centers differed significantly from each other.
Statistical significance was defined as p < .05 and all analyses were conducted using SPSS 14.0 for Windows (SPSS, Chicago, IL).
RESULTS
Thirteen-thousand five-hundred fifty-two children met study criteria in the PHIS dataset; of these, 2812 (21%) received care in a CPCCRN site. Select demographic and clinical features are compared within CPCCRN centers and between CPCCRN and non-CPCCRN centers in Table 1 . Patients treated at most centers had a median age of 6 yrs and were predominantly male. Although race and ethnicity varied across centers, blacks and Hispanics were overrepresented compared to the United States pediatric population census information (19). CPCCRN centers had fewer white (16% vs. 29%), more black (61% vs. 42%), and fewer Hispanic children (11% vs. 13%) than the non-CPCCRN centers. Government-sponsored insurance was the most common payer.
Although the majority of children were first treated in the PHIS hospital pediatric emergency department, this varied significantly among CPCCRN (33%-89%), and between CPCCRN and non-CPCCRN centers (75% vs. 66%). Median PICU stays were statistically different across CPCCRN centers but appeared clinically similar (median 1 or 2 days at each center). Complications in CPCCRN centers, including pneumothorax (0%-0.6%), cardiac arrest (0.2%-2%), aspiration (0.2%-2%), and death (0.2%-2%) were rare and similar overall to those of non-CPCCRN centers. Table 2 compares asthma treatments across CPCCRN centers and between CPCCRN and non-CPCCRN centers. Because the study size is large, many therapies differed significantly between CPCCRN and non-CPCCRN centers but were clinically similar (e.g., intravenous terbutaline 24% vs. 21%, p = .002). However, administration of intravenous terbutaline varied substantially across CPCCRN centers (11%-74%). The database does not have information on dose; thus, escalation of inhaled or intravenous β2 agonists could not be evaluated. Use of inhaled anticholinergics (41%-84%), intravenous magnesium (23%-64%), and methylxanthines (0%-46%) all varied across CPCCRN centers, whereas between CPCCRN and non-CPCCRN centers only the use of inhaled anticholinergics (59% vs. 71%) and intravenous magnesium (37% vs. 43%) differed by clinically important magnitudes.
Use of advanced respiratory support differed significantly across CPCCRN centers: heliox (0%-28%), noninvasive ventilation (0.3%-6%), and invasive ventilation (6%-26%). Comparison of CPCCRN and non-CPCCRN centers use of mechanical respiratory support was: heliox (15% vs. 8%), noninvasive ventilation (3% vs. 5%), and invasive ventilation (10% vs.12%). With the exception of heliox administration, use of mechanical support appeared to be clinically similar between CPCCRN and non-CPCCRN centers. Use of blood gas testing, chest radiography, and magnesium measurements varied significantly across CPCCRN centers, but overall use did not differ between CPCCRN and non-CPCCRN centers.
Readmission after the index admission was tracked for CPCCRN center patients and 12% were admitted to the pediatric hospital emergency department a median of 5 months later. Readmission to the hospital was even more common (17%) a median of 4 months later. Additionally, 6% were readmitted to the PICU a median of 4 months after the initial asthma PICU admission.
To evaluate children treated for the most severe asthma, a subgroup (n = 303) that received either noninvasive mechanical ventilation and/or invasive mechanical ventilation at a CPCCRN site are presented in Table 3 and Table 4 . The median length of PICU stay varied significantly by site with a median range of 2 to 4 days; however, duration of invasive ventilation did not significantly differ across CPCCRN sites. Complications were relatively low: pneumothorax (0%-4%), aspiration (2%-11%), and cardiorespiratory arrest (2%-15%) did not differ significantly across CPCCRN sites. The mean mortality rate was 2%.
Therapies and monitoring in this subgroup are reported in Table 4 . There was significant variation for treatment use across CPCCRN centers, including intravenous terbutaline (20%-85%), ipratropium bromide (22%-89%), intravenous magnesium sulfate (27%-62%), and methylxanthines (0%-56%). The proportion of children intubated before PICU care ranged from 43% to 87% across CPCCRN centers. Comparing CPCCRN to non-CPCCRN centers, significantly more were intubated before PICU care in CPCCRN centers (62% vs. 47%). Whereas similar proportions were intubated in a PICU (30% vs. 28%), use of noninvasive ventilation without invasive ventilation was more common at non-CPCCRN centers (8% vs. 25%). Testing blood gases and magnesium levels as well as radiographic imaging varied significantly across CPCCRN centers. Readmission after the initial PICU asthma admission in this subgroup was 9% to the emergency department, 16% to the hospital, and 6% to the PICU.
To more fully evaluate ventilatory support in PICU asthma care, all children (CPCCRN and non-CPCCRN centers) treated with noninvasive or invasive mechanical ventilation were stratified by site of endotracheal intubation and type of 
Pediatric intensive care unit length of stay support (Table 5 ). Significantly more children (41% vs. 25%) were treated with noninvasive ventilation and significantly fewer (41% vs. 58%) were intubated before PICU care when treated in a PHIS hospital emergency department compared to other sites of pre-PICU care. Children treated with noninvasive ventilation were significantly older (median age, 8 yrs) than those intubated in the PICU without a trial of noninvasive ventilation (median age, 6 yrs).
Children intubated outside the PICU had significantly shorter PICU and hospital LOS compared to those treated solely with noninvasive ventilation. Forty percent of children (259/642) initially treated with noninvasive ventilator support progressed to invasive ventilation. The median duration of invasive ventilation was 3 days for children intubated in the PICU without a trial of noninvasive ventilation compared to 2 days for those intubated after noninvasive ventilation (not significantly different); however, LOS in the PICU was significantly less for those treated with a trial of noninvasive ventilation before intubation.
DISCUSSION
In this large cohort of children treated for asthma in a PICU, both medication use and mechanical support varied widely within the CPCCRN centers but, on average, the CPCCRN centers were representative of a large group of children's hospitals in the United States that contribute data to PHIS. There was large variation in care for children who responded to initial medication therapy as well as children who were nonresponders treated with mechanical ventilator support. Complications such as air leak syndrome, aspiration, and death were uncommon in both groups. PICU LOS differed by 1-2 days, but duration of ventilation did not differ across CPCCRN sites among patients treated with mechanical respiratory support. Intubation for mechanical ventilator support most commonly occurred outside the PICU, but those intubated in the PICU appeared to have more severe disease with longer PICU LOS and duration of mechanical support.
The current variation in critical asthma care reflects the lack of high-quality research for "best practice." The World Health Organization and the National Heart, Lung, and Blood Institute recommendations do not address critical care for asthma in detail and differ slightly in recommended "second tier" therapies (3, 4). After "recommended" therapies including supplemental oxygen, systemic corticosteroids, inhaled β2 agonists, and ipratropium, the panels recommend "consideration" of other therapies (3, 4), which are not prioritized and lack a pathway for stepwise escalation. Wide variation in severe asthma care previously has been reported (7, 8, 20, 21) and the CPCCRN centers on average appear to utilize asthma therapies in a manner representative of current national practice. The most prominent recent change in medication treatment for asthma is increased use of intravenous magnesium sulfate (7) .
The overall use of intravenous β-agonists (terbutaline) in PHIS PICUs was 22% and varied widely. However, the National Heart, Lung, and Blood Institute expert asthma guidelines specifically 69 (20) 150 (11) 26 (17) 347 (74) 46 (12) 29 (54) 667 (24) 2253 (21) Inhaled albuterol 64 (19) 150 (11) 26 (17) 262 (56) 44 (11) 29 (54) 575 (20) 2125 (20) (9) 36 (3) 33 (21) 63 (13) 28 (7) 10 (19) 202 (7) 712 ( 282 (23) 78 (6) 43 (28) 6 (1) 18 (5) 20 (6) 17 (3) 2 (1) 30 (6) 49 (14) 112 (8) 40 (26) 48 (10) 23 (6) 9 (17) 281 (10) 1258 (12) Tests in pediatric intensive care unit, median (interquartile range) c N, blood gas categorize intravenous β2 agonist as a therapy with no proven benefit above aerosolized administration and greater risk of toxicity (3) . Isoproterenol is specifically identified as "not recommended" because of potential myocardial toxicity (22) . A Cochrane review of 15 studies reported no evidence to support use of intravenous β2 agonists in emergency department patients, including adults and children, to prevent hospital admission (23) . Of note, intravenous β2 agonists are commonly used outside the United States for severe asthma for PICU care (24) and systemic delivery of β2 agonists are believed to result in more consistent drug delivery than aerosolized medication through a ventilator to a patient with severely obstructed airways. The persistent marked variability provides clinical data supporting equipoise for future studies regarding optimal medications for severe asthma.
Noninvasive ventilation is a potential asthma care study intervention. A greater proportion of children treated in the PHIS hospital emergency department was started on noninvasive ventilation compared to children triaged outside the PHIS emergency department, which likely reflects respiratory therapy expertise as well as physician comfort with noninvasive ventilation in children. Forty percent of children started on noninvasive ventilation "failed" and were subsequently treated with invasive ventilation. Small studies report the feasibility of noninvasive ventilation for pediatric asthma (10, 25) and adults have rapid improvement in pulmonary function tests after institution of noninvasive ventilation (26) . An initial trial of noninvasive ventilation did not increase PICU stay compared to children directly intubated in the PICU and was associated with decreased length of mechanical ventilator support. However, the lack of illness severity measurements limits conclusions regarding the efficacy of noninvasive ventilation to decrease the need for invasive ventilation.
Appropriate outcome measures for severe asthma studies require consideration. PICU LOS, mechanical ventilation, and complications are potential candidates but have limitations. Among our entire study group, the PICU LOS was a median of 1 day (interquartile range, 1-3). A child may be medically appropriate to transfer out of a PICU, but actual transfer depends on nonmedical factors such as nurse staffing and bed availability. PICU LOS differed more for the subset of children who received mechanical ventilator support, but duration of ventilation was significantly shorter for those intubated before admission to the PICU. Simple receipt of intubation therefore would be a poor outcome measure for studies of asthma therapy in the PICU. Complications such as air leak, aspiration, cardiac arrest, and death are uncommon outcomes even among the subset of children treated with mechanical respiratory support and would require a large study to have sufficient power to determine study intervention efficacy.
Although care variation can be ascribed in part to differences in illness severity, some of it is likely attributable to local practice patterns. Roberts et al (9) evaluated a multicentered retrospective cohort of children treated in intensive care units for asthma and reported that patient care differed between hospitals with physicians at some institutions more likely to intubate and mechanically ventilate children with similar Paco 2 and PRISM III scores. Our present data also document wide variability in blood sample testing, imaging studies, and 
2 (5) 4 (6) 2 (8) 1 (11) 13 (4) Cardiac arrest 3 (6) 3 (3) 1 (2) 2 (3) 4 (15) 1 (11) 14 (5) Death a 1 (2) 1 (1) 1 (2) 1 (2) administration of antibiotics (particularly among patients who received mechanical support), but with similar clinical outcomes across centers. Perhaps the most fundamental tool needed for development of meaningful severe asthma management research is a validated scoring system to aid assessment of disease severity and the need for increased therapy, and to improve consistency during care escalation and de-escalation. Although the National Institutes of Health Expert Panel for the "Guidelines for the Diagnosis and Management of Asthma" recommends use of peak flow meters to monitor response to therapy (3), many young or severely dyspneic children cannot perform such maneuvers. The Global Initiative for Asthma has a chart that includes physical findings, blood gas values, and peak expiratory flow rates to aid clinicians in asthma severity assessment but does not include a scoring system or recommendations for escalating care for increasing disease severity (4). Studies have not validated clinical asthma scoring systems to predict end points relevant for critical asthma such as response to therapy, mechanical support, or retention of carbon dioxide (27) .
Although this study has the advantage of a very large sample of children treated in PICUs for a primary diagnosis of asthma, it has some limitations. Many physicians would expect 100% of children to receive corticosteroids and inhaled β2 agonists, which was not the case in our population. It is possible that some received corticosteroids and/or inhaled β-agonists but were not billed for those treatments, or the PICU stay was sufficiently short that doses administered in the emergency department were sufficient. Because exposure to various asthma treatments was based on billing, we also cannot be sure if the individual patient actually received the therapy. For example, the number of patients billed for neuromuscular blocking agent was higher than the number billed for mechanical ventilation at several of the CPCCRN hospitals. Perhaps neuromuscular blocking agents were ordered to the bedside but were not administered to the patients because of clinical improvement. The Clinical Transaction Classification codes and billing data did not perfectly correspond with the International Classification Diseases version 9 procedure codes. A major limitation is that the pharmacy and procedure data are recorded daily rather than hourly, which prevents assessment of care escalation. Furthermore, the pharmacy data do not include dose or interval of administration. This precludes assessment of dose variation and escalation that can be large for inhaled β-agonists and intravenous terbutaline (14) . Finally, lack of severity of illness measures limit conclusions regarding efficacy of therapy and differences in LOS by site of intubation.
This study supports previous observations that PICU asthma care varies widely between centers with marked variation in medication and mechanical support as well as testing. Mortality and complications such as air leak syndrome are uncommon and use of "rescue" therapies (e.g., inhaled anesthetic agents, extracorporeal membrane oxygenation) is rare. New information reported included data regarding duration of ventilation and LOS by site of intubation. Some variation in care may be partly attributable to disease severity, but it is also likely that some is attributable to local and physician practice patterns. A validated severity of asthma scoring system is important to document disease severity to develop and rigorously follow-up clinical management pathways to decrease care variation and hopefully improve outcomes. Timing of intubation, either before or during PICU admission, is associated with LOS and duration of ventilation and therefore should be considered as a potential confounding factor in future interventional trials. The current large variation in care for severe pediatric asthma provides equipoise to further study the impact of specific treatment strategies on asthma outcomes and optimize care for this critically ill group of children.
